EGFR and non-small cell lung carcinoma: Recently, several somatic mutations in the EGFR gene have been linked with favourable response to treatment with anti-EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, in non-small cell lung cancer (NSCLC) patients (Scaltriti and Baselga, 2006).